You were redirected to http://www.grifols.com/en/analyst-coverage .

Click the following link if you want to dismiss this redirect and access the original URL: Link .

Skip to Content

First Half 2026 Earnings Results on July 28, 2026. at 5:35pm CET. Webcast scheduled at 6:30pm CET

Access webcast
Access webcast
  • Contact us
  • International Headquarters
  • Adverse reactions - Pharmacovigilance
  • Grifols Ethics Line
  • Change Language
  • Español
  • Deutsch
  • 中文
'Grifols.com' logo 'Grifols.com' logo

  • Company

    Since 1909, Grifols has worked to improve the health and well-being of people around the world.

    Read more

    • Corporate Structure

      • Board of Directors
      • Management Team
    • What We Do 
      • Biopharma
      • Diagnostic
      • Bio Supplies
      • Healthcare Solutions for Hospitals
    • Mission, vision and values 
    • Ethics and Compliance 
    • Our History 
    • Grifols Museum 
      • La Casa: Where It All Began
      • The Plant: People Helping People
      • The World: From Family Business to Global Company
    • Grifology 
      • The Cabinet
    • Grifols Engineering 
    Every action we take is motivated by our mission to improve people's lives. 
    Our unique and remarkable history combines scientific expertise with a desire to serve patients and society. 
    We develop, produce and market innovative medicines, solutions and services in more than 110 countries. 

  • Innovation

    Grifols is full speed ahead on developing the next innovative breakthroughs across multiple therapeutic areas.  

    Read more
    • Plasma Powerhouse 
    • Beyond Plasma 
    • Key Therapeutic Areas 
      • Immunology
      • Hepatology and Intensive Care
      • Pulmonology
      • Hematology
      • Neurology
      • Infectious Diseases
      • Further Therapeutic Opportunities
    • CHRONOS-PD: Plasma Science in Parkinson’s Research 
    • Extending Our Innovative Reach 
      • Team Up with Grifols Innovation and New Technologies
      • Scientific Awards and Programs
    • Connecting Knowledge - Our R&D Network 
    We apply our growing knowledge of plasma to change healthcare. 
    Our treatments are enhancing people’s well-being and quality of life. 
    We’re drawing on a broad scientific base to continue innovating. 

  • Sustainability

    Grifols' longstanding commitment to people and the planet entails helping society on all fronts.

    Read more

    • Social Commitment

      • Supporting Patients
      • Supporting Donors
      • Our People
      • Social Action
    • Environmental Responsibility 
    • Ethical Leadership 
    • Sustainability Reports & Corporate Policies 
    2025 Integrated and Sustainability Annual Report 
    Innovating with purpose to drive positive impact 
  • Products

  • Investors

    Read more

    • Stock Information

      • Stock and share capital
      • Dividends
      • Major Holders and Treasury Stock
      • Agreements between Shareholders
      • Analyst Coverage

    • Financials

      • Financial Results
      • Annual Accounts
      • Fixed Income and Credit Ratings
      • Average Period of Payment to Suppliers
      • Key Figures
    • Press Releases 
    • Presentations and Events 
    • Agenda 

    • Communications with CNMV and SEC

      • CNMV
      • SEC
      • Other Relevant Information
      • Inside Information
      • Significant events until 8 February 2020
    • Corporate Stewardship Reports 

    • Corporate Governance

      • Board of Directors
      • General Shareholders’ Meeting
      • Annual Corporate Governance Report
      • Directors' Remuneration Report
      • Articles of Association
      • Corporate Policies
    • Mergers 
    • Biotest: Voluntary Takeover Offer | Freiwilliges Übernahmeangebot (2021) 
    • Biotest: Acquisition offer (delisting) / freiwilliges Erwerbsangebot (Delisting) (2025) 
    Presentation First-Quarter 2026 Results 
    2025 Integrated and Sustainability Annual Report 

  • Careers

    People are at the heart of our business. We are committed to continued investment in training and development.

    Explore Opportunities
    • Why Grifols 
      • People & Culture
      • Our teams
    • Training and Development 
    • Hiring Journey 
    • Early Careers 

  • Media

    Latest news about the company and contact information for journalists and communication professionals.

    Read more
    • Newsroom 
    • Events 
      • Q1 2026 Financial Results
      • General Shareholders' Meeting 2026
    • Media Contacts 
    • Media Center 

  • Suppliers

    At Grifols, we believe in long-term, mutually trusting relationships with our partners.

    More details
    • Join Grifols Supplier Network 
  • Change Language
  • Español
  • Deutsch
  • 中文
  • Company
    • Company
    • Corporate Structure
      • Board of Directors
      • Management Team
    • What We Do
      • What We Do
      • Biopharma
      • Diagnostic
      • Bio Supplies
      • Healthcare Solutions for Hospitals
    • Mission, vision and values
    • Ethics and Compliance
    • Our History
    • Grifols Museum
      • Grifols Museum
      • La Casa: Where It All Began
      • The Plant: People Helping People
      • The World: From Family Business to Global Company
    • Grifology
      • Grifology
      • The Cabinet
    • Grifols Engineering
  • Innovation
    • Innovation
    • Plasma Powerhouse
    • Beyond Plasma
    • Key Therapeutic Areas
      • Key Therapeutic Areas
      • Immunology
      • Hepatology and Intensive Care
      • Pulmonology
      • Hematology
      • Neurology
      • Infectious Diseases
      • Further Therapeutic Opportunities
    • CHRONOS-PD: Plasma Science in Parkinson’s Research
    • Extending Our Innovative Reach
      • Extending Our Innovative Reach
      • Team Up with Grifols Innovation and New Technologies
      • Scientific Awards and Programs
    • Connecting Knowledge - Our R&D Network
  • Sustainability
    • Sustainability
    • Social Commitment
      • Supporting Patients
      • Supporting Donors
      • Our People
      • Social Action
    • Environmental Responsibility
    • Ethical Leadership
    • Sustainability Reports & Corporate Policies
  • Products
  • Investors
    • Investors
    • Stock Information
      • Stock and share capital
      • Dividends
      • Major Holders and Treasury Stock
      • Agreements between Shareholders
      • Analyst Coverage
    • Financials
      • Financial Results
      • Annual Accounts
      • Fixed Income and Credit Ratings
      • Average Period of Payment to Suppliers
      • Key Figures
    • Press Releases
    • Presentations and Events
    • Agenda
    • Communications with CNMV and SEC
      • CNMV
      • SEC
      • Other Relevant Information
      • Inside Information
      • Significant events until 8 February 2020
    • Corporate Stewardship Reports
    • Corporate Governance
      • Board of Directors
      • General Shareholders’ Meeting
      • Annual Corporate Governance Report
      • Directors' Remuneration Report
      • Articles of Association
      • Corporate Policies
    • Mergers
    • Biotest: Voluntary Takeover Offer | Freiwilliges Übernahmeangebot (2021)
    • Biotest: Acquisition offer (delisting) / freiwilliges Erwerbsangebot (Delisting) (2025)
  • Careers
    • Careers
    • Why Grifols
      • Why Grifols
      • People & Culture
      • Our teams
    • Training and Development
    • Hiring Journey
    • Early Careers
  • Media
    • Media
    • Newsroom
    • Events
      • Events
      • Q1 2026 Financial Results
      • General Shareholders' Meeting 2026
    • Media Contacts
    • Media Center
  • Suppliers
    • Suppliers
    • Join Grifols Supplier Network

Connect with us

Investors
Grifols Investors Stock Information Analyst Coverage

Analyst Coverage

 

The information contained on the Grifols worldwide website is not applicable to all countries. For specific information on the products and services available in your country, please select your country from the list included in the corresponding section. The purpose of this website is to provide information about Grifols' products and services, and it is not intended for, nor may it be construed as, promoting any products in countries in which they are not approved.

'Grifols.com' logo 'Grifols.com' logo
About Us

About Us

  • Company
  • Sustainability
  • Innovation
  • Products
  • Investors
  • Careers
  • Media
Top websites

Top websites

  • Grifols Plasma
  • Grifols Diagnostics Solutions
  • Grifols Scientific Awards
  • Grifols Engineering
  • Grifols Egypt for Plasma Derivatives
  • Victor Grifols i Lucas Foundation
  • Probitas Foundation
  • J.A. Grifols Foundation
Legal & Help

Legal & Help

  • Privacy Notices
  • Cookies Policy
  • Cookies Settings
  • Terms of Use
  • Grifols Ethics Line
  • Contact
  • Glossary

Connect with us

© 2026 Grifols, S.A. All rights reserved worldwide.